| Name | Title | Contact Details |
|---|---|---|
Kelly Vaillant |
Director of Global Transparency Strategy and Compliance | Profile |
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
CRi is dedicated to providing personalized resources to youth & adults with mental health needs & developmental disabilities.
Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 18 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications, and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions.
Fluid Air, Inc. is a Aurora, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Hemarus is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.